Advances in immuno-oncology have significantly expanded the treatment landscape of advanced and metastatic melanoma , with evolving guideline recommendations shaping first-line therapeutic decisions . To explore the positioning of dual checkpoint inhibition within the current treatment paradigm, including guideline perspectives and case-based decision-making, Bristol Myers Squibb ® , India invites you to an exclusive session under the lecture series “ Re-imagine Melanoma care: Unlocking Novel IO pathway with LAG-3 & PD-1 Blockage. ” Join expert Oncologist Dr. Navile Aditya Murali for Session 4 on “ Role of Nivo/rela in the management of advanced melanoma ” on Saturday, 23rd May 2026 , from 7:00 PM to 8:00 PM IST .
Don’t Miss This Insightful Session! ##DISCLAIMER## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we…
